ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated. If you have any questions, please contact Marianne Reed at mreed@ku.edu .

Biopharmaceutical Innovation & Optimization Center Scholarly Works

Browse by

 

 

Recent Submissions

  • Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex 

    Weir, Scott J.; Dandawate, Prasad; Standing, David; Bhattacharyya, Sangita; Ramamoorthy, Prabhu; Rangarajan, Parthasarathy; Wood, Robyn; Brinker, Amanda E.; Woolbright, Benjamin L.; Tanol, Mehmet; Ham, Tammy; McCulloch, William; Dalton, Michael; Reed, Gregory A.; Baltezor, Michael J.; Jensen, Roy A.; Taylor, John A., III; Anant, Shrikant (Springer Nature, 2021-05-31)
    Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a number of solid and hematologic malignancies. Its clinical utility as an oral anticancer agent, however, ...

  • A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies 

    Williamson, Stephen K.; Johnson, Gary A.; Maulhardt, Holly A.; Moore, Kathleen M.; McMeekin, D. S.; Schulz, Thomas K.; Reed, Gregory A.; Roby, Katherine F.; Mackay, Christine B.; Smith, Holly J.; Weir, Scott J.; Wick, Jo A.; Markman, Maurie; diZerega, Gere S.; Baltezor, Michael J.; Espinosa, Jahna; Decedue, Charles J. (Springer Verlag, 2015-05)
    PURPOSE: This multicenter, open-label, dose-escalating, phase I study evaluated the safety, tolerability, pharmacokinetics and preliminary tumor response of a nanoparticulate formulation of paclitaxel (Nanotax®) administered ...